(19) World Intellectual Property Organization

International Bureau



(43) International Publication Date 21 April 2005 (21.04.2005)

PCT

(10) International Publication Number WO 2005/034950 A1

- (51) International Patent Classification⁷: A61K 31/4365, A61P 35/00
- (21) International Application Number:

PCT/GB2004/004216

- (22) International Filing Date: 5 October 2004 (05.10.2004)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0323810.2

10 October 2003 (10.10.2003) GB

- (71) Applicant (for all designated States except US): VER-NALIS (CAMBRIDGE) LIMITED [GB/GB]; Granta Park, Abington, Cambridge CB1 6GB (GB).

- (74) Agent: WALLS, Alan, J.; Vernalis (Cambridge) Limited, Granta Park, Abington, Cambridge CB1 6GB (GB).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,

(72) Inventors; and
(75) Inventors/Applicants (for US only): DRYSDALE,
Martin, James (GB/GB); Vernalis (Cambridge) Limited,
Granta Park, Abington, Cambridge CB1 6GB (GB).

DYMOCK, Brian, William (GB/GB); Evotec OAI, 151
Milton Park, Abington, Oxfordshire OX14 4SD (GB).

BARRIL-ALONSO, Xavier (ES/GB); Vernalis (Cambridge) Limited, Granta Park, Abington, Cambridge CB1
6GB (GB).

(54) Title: PYRIDOTHIOPHENE COMPOUNDS

| Compounds of formula (I) in therapy, particularly for the treatment of a disorder mediated by excessive or inappropriate HSP90 activity formula (I), wherein R₂ is a group of formula (IA): -(Ar')_m-(Alk')_b-(Z),-Alk2 and Q being as defined in the specification; m, p, r and s are independently 0 or 1; R3 is hydrogen, an optional substituent, or an optionally substituted (C1-C6)alkyl, aryl or heteroaryl radical; and R4 is a carboxylic ester, carboxamide or sulfonamide group; or a salt, N-oxide, hydrate, or solvate thereof.